Bipartisan House bills target price-gouging, monopolies and transparency for taxpayer funded COVID-19 drugs Read Full Article Back to Economic News Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.